<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04161963</url>
  </required_header>
  <id_info>
    <org_study_id>ICCME</org_study_id>
    <nct_id>NCT04161963</nct_id>
  </id_info>
  <brief_title>Incidence of Sub-clinical Cystoid Macular Edema After Cataract Surgery</brief_title>
  <acronym>ICCME</acronym>
  <official_title>Incidence of Sub-clinical Cystoid Macular Edema After Cataract Surgery</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Zurich</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University of Zurich</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Cystoid macular edema (CME) can limit visual acuity after cataract surgery. Little is known
      whether the incidence is similar between standard ultrasound phacoemulsification cataract
      surgery (phaco), femtolaser assisted cataract surgery (FLACS), and combined
      phacoemulsification cataract surgery plus micro invasive glaucoma surgery (phaco+MIGS)
      procedures.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Subclinical cystoid macular edema (CME) can limit visual acuity after cataract surgery.
      Little is known whether the incidence is similar between standard ultrasound
      phacoemulsification cataract surgery (phaco), femtolaser assisted cataract surgery (FLACS),
      and combined phacoemulsification cataract surgery plus micro invasive glaucoma surgery
      (phaco+MIGS) procedures.

      The investigators hypothesize that CME incidence will be in the following order: FLACS &lt;
      phaco &lt; phaco+MIGS due to the increase of inflammation with the different surgical
      procedures.

      The study is designed as a single centre, prospective study. The study includes patients with
      a diagnosis of cataract or cataract and glaucoma who will undergo one of the three above
      mentioned sürgical procedures at the Department of Ophthalmology at the UniversityHospital
      Zurich (USZ), Zurich, Switzerland. CME will be assessed by optical coherence tomography of
      the macular with Heidelberg Spectralis SD-OCT of the Macular at: baseline (i.e.
      preoperative), 1 week, 1 month, 3 months, and 6 months post-surgery. Furthermore, a swept
      source Optical Coherence Tomography Angiography (OCT-A) using Zeiss Plex Elite 9000 will be
      performed at: baseline (i.e. preoperative), 1 week, 1 month, and 6 months post-surgery to
      image the retinal vessels.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">March 4, 2019</start_date>
  <completion_date type="Anticipated">December 31, 2021</completion_date>
  <primary_completion_date type="Anticipated">December 31, 2021</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Case-Control</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>incidence of CME</measure>
    <time_frame>baseline/preop</time_frame>
    <description>incidence of subclinical cystoid macular edema</description>
  </primary_outcome>
  <primary_outcome>
    <measure>incidence of CME</measure>
    <time_frame>1 week postop +/- 4 days</time_frame>
    <description>incidence of subclinical cystoid macular edema</description>
  </primary_outcome>
  <primary_outcome>
    <measure>incidence of CME</measure>
    <time_frame>1 month postop +/-2 weeks</time_frame>
    <description>incidence of subclinical cystoid macular edema</description>
  </primary_outcome>
  <primary_outcome>
    <measure>incidence of CME</measure>
    <time_frame>3 months postop +/-2 weeks</time_frame>
    <description>incidence of subclinical cystoid macular edema</description>
  </primary_outcome>
  <primary_outcome>
    <measure>incidence of CME</measure>
    <time_frame>6 months postop +/-2 weeks</time_frame>
    <description>incidence of subclinical cystoid macular edema</description>
  </primary_outcome>
  <number_of_groups>3</number_of_groups>
  <enrollment type="Anticipated">150</enrollment>
  <condition>Cataract</condition>
  <condition>Glaucoma</condition>
  <arm_group>
    <arm_group_label>Phaco</arm_group_label>
    <description>tandard ultrasound phacoemulsification cataract surgery</description>
  </arm_group>
  <arm_group>
    <arm_group_label>FLACS</arm_group_label>
    <description>femtolaser assisted cataract surgery</description>
  </arm_group>
  <arm_group>
    <arm_group_label>phaco+MIGS</arm_group_label>
    <description>combined phacoemulsification cataract surgery plus micro invasive glaucoma surgery</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>SD-OCT</intervention_name>
    <description>Optical Coherence Tomography of the maculy with Heidelberg Spectralis SD-OCT</description>
    <arm_group_label>FLACS</arm_group_label>
    <arm_group_label>Phaco</arm_group_label>
    <arm_group_label>phaco+MIGS</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>OCT-A</intervention_name>
    <description>swept source Optical Coherence Tomography Angiography with Zeiss Plex Elite 9000 of the macula</description>
    <arm_group_label>FLACS</arm_group_label>
    <arm_group_label>Phaco</arm_group_label>
    <arm_group_label>phaco+MIGS</arm_group_label>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Patient who will undergo cataract surgery or combined catarct MIGS glaucoma surgery at the
        University Hospital Zurich
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patients with a diagnosis of cataract or

          -  Patients with a diagnosis of cataract and open angle glaucoma

          -  Signed lnformed Consent

          -  Patients at the age of 18 or older

        Exclusion Criteria:

          -  Loss of follow up, i.e. not available during the post-operation follow-up inteval.

          -  Previous known of CME, macular pathology (e.g., Diabetes, exudative age-related
             macular degeneration, status post retinal vein occlusion) or posterior uveitis.

          -  Patient unable to understand the study due to cognitive or linguistic incapacity.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Marc Töteberg-Harms, MD, FEBO</last_name>
    <role>Principal Investigator</role>
    <affiliation>University Hospital Zurich, Department of Ophthalmology</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Marc Töteberg-Harms, MD, FEBO</last_name>
    <phone>+41442558794</phone>
    <phone_ext>+41442558794</phone_ext>
    <email>marc.toeteberg@usz.ch</email>
  </overall_contact>
  <location>
    <facility>
      <name>Department of Ophthalmology</name>
      <address>
        <city>Zurich</city>
        <state>ZH</state>
        <zip>8091</zip>
        <country>Switzerland</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Marc Toeteberg-Harms, MD, FEBO</last_name>
      <phone>+41 44 255 - 1111</phone>
      <email>marc.toeteberg@usz.ch</email>
    </contact>
  </location>
  <location_countries>
    <country>Switzerland</country>
  </location_countries>
  <verification_date>March 2020</verification_date>
  <study_first_submitted>November 11, 2019</study_first_submitted>
  <study_first_submitted_qc>November 11, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">November 13, 2019</study_first_posted>
  <last_update_submitted>March 24, 2020</last_update_submitted>
  <last_update_submitted_qc>March 24, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">March 26, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Cataract</keyword>
  <keyword>Glaucoma</keyword>
  <keyword>cystroid macular edema</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Glaucoma</mesh_term>
    <mesh_term>Cataract</mesh_term>
    <mesh_term>Macular Edema</mesh_term>
    <mesh_term>Capsule Opacification</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

